[FG] Grosse Gerrit

Cao, J. et al. (2024) ‘DNA-sensing inflammasomes cause recurrent atherosclerotic stroke’, Nature, 633(8029), pp. 433–441. Available at: https://doi.org/10.1038/s41586-024-07803-4.

Diener, H.-C. et al. (2024) ‘Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study’, European Stroke Journal, 9(3), pp. 696–703. Available at: https://doi.org/10.1177/23969873241242239.

Jochmann, S.L. et al. (2024) ‘Sex-Specific Risk Factors of Nonstenotic Carotid Plaque in Embolic Stroke of Unknown Source: A Case-Control Study’, Stroke, 55(2), pp. 296–300. Available at: https://doi.org/10.1161/STROKEAHA.123.044833.

Dirks, M. et al. (2024) ‘Long-Term Follow-Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon-Free and Interferon-Based Hepatitis C Virus Treatment’, Journal of Viral Hepatitis [Preprint]. Available at: https://doi.org/10.1111/jvh.14033.

Smith, Eric E. et al. (2024) ‘Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes’, Stroke, 55, pp. 392–402. Available at: https://doi.org/10.1161/strokeaha.123.043198.

Grosse, G.M. et al. (2023) ‘Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study’, International Journal of Stroke, 18(10), pp. 1169–1177. Available at: https://doi.org/10.1177/17474930231184366.

Hupe, J. et al. (2023) ‘Interplay between driveline infection, vessel wall inflammation, cerebrovascular events and mortality in patients with left ventricular assist device’, Scientific Reports, 13(1). Available at: https://doi.org/10.1038/s41598-023-45110-6.

Worthmann, H., Ernst, J. and Grosse, G.M. (2023) ‘What is confirmed in the treatment of ischemic stroke Was ist gesichert in der Therapie des ischämischen Schlaganfalls?’, Innere Medizin (Germany), 64(12), pp. 1143–1153. Available at: https://doi.org/10.1007/s00108-023-01622-x.

Sievering, E.M. et al. (2023) ‘Diagnostic value of carotid intima-media thickness and clinical risk scores in determining etiology of ischemic stroke’, European Stroke Journal, 8(3), pp. 738–746. Available at: https://doi.org/10.1177/23969873231182492.

Ernst, J. et al. (2023) ‘Unraveling Mechanisms of Cryptogenic Stroke at the Genetic Level: A Systematic Literature Review’, Journal of the American Heart Association, 12(15). Available at: https://doi.org/10.1161/JAHA.123.029843.

Grosse, G.M. et al. (2023) ‘ADAMTS-13 activity in stroke of known and unknown cause: Relation to vascular risk factor burden’, Frontiers in Neurology, 13. Available at: https://doi.org/10.3389/fneur.2022.1045478.

Sieweke, J.-T. et al. (2022) ‘Circulating fibroblast activation protein α is reduced in acute ischemic stroke’, Frontiers in Cardiovascular Medicine, 9. Available at: https://doi.org/10.3389/fcvm.2022.1064157.

Faber, D. et al. (2022) ‘Towards the Validation of Executive Functioning Assessments: A Clinical Study’, Journal of Clinical Medicine, 11(23). Available at: https://doi.org/10.3390/jcm11237138.

Hasse, I.M.C. et al. (2022) ‘Circulating Inflammatory Biomarkers in Early Prediction of Stroke-Associated Infections’, International Journal of Molecular Sciences, 23(22). Available at: https://doi.org/10.3390/ijms232213747.

de Buhr, N. et al. (2022) ‘Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic Thrombocytopenia’, Frontiers in Immunology, 13. Available at: https://doi.org/10.3389/fimmu.2022.879157.

Grosse, G.M. et al. (2022) ‘Endogenous Deoxyribonuclease Activity and Cell-Free Deoxyribonucleic Acid in Acute Ischemic Stroke: A Cohort Study’, Stroke, 53(4), pp. 1235–1244. Available at: https://doi.org/10.1161/STROKEAHA.121.036299.

Grosse, G.M. et al. (2022) ‘Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion-Association with Success of Endovascular Treatment’, Thrombosis and Haemostasis, 122(4), pp. 623–632. Available at: https://doi.org/10.1055/a-1544-5431.

Sieweke, J.-T. et al. (2022) ‘Echocardiographic Parameters to Predict Atrial Fibrillation in Clinical Routine—The EAHsy-AF Risk Score’, Frontiers in Cardiovascular Medicine, 9. Available at: https://doi.org/10.3389/fcvm.2022.851474.

Ernst, J. et al. (2022) ‘Advancement of door-to-needle times in acute stroke treatment after repetitive process analysis: never give up!’, Therapeutic Advances in Neurological Disorders, 15. Available at: https://doi.org/10.1177/17562864221122491.

Dirks, M. et al. (2021) ‘Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation’, European Journal of Nuclear Medicine and Molecular Imaging, 49(1), pp. 234–245. Available at: https://doi.org/10.1007/s00259-021-05398-w.

Grosse, G.M. et al. (2021) ‘Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study’, European Stroke Journal, 6(4), pp. 438–444. Available at: https://doi.org/10.1177/23969873211060219.

Grosse, G.M. et al. (2021) ‘Circulating microRNAs in Symptomatic and Asymptomatic Carotid Stenosis’, Frontiers in Neurology, 12. Available at: https://doi.org/10.3389/fneur.2021.755827.

Deutsch, N.R. et al. (2021) ‘Autoantibodies against the NMDAR subunit NR1 are associated with neuropsychiatric outcome after ischemic stroke’, Brain, Behavior, and Immunity, 96, pp. 73–79. Available at: https://doi.org/10.1016/j.bbi.2021.05.011.

Weissenborn, K. et al. (2021) ‘Endovascular Treatment of Acute Ischemic Stroke in Clinical Practice: Analysis of Workflow and Outcome in a Tertiary Care Center’, Frontiers in Neurology, 12. Available at: https://doi.org/10.3389/fneur.2021.657345.

Grosse, G.M. et al. (2020) ‘Nonstenotic Carotid Plaque in Embolic Stroke of Undetermined Source: Interplay of Arterial and Atrial Disease’, Stroke, 51(12), pp. 3737–3741. Available at: https://doi.org/10.1161/STROKEAHA.120.030537.

Stauss, R.D. et al. (2020) ‘Distinct systemic cytokine networks in symptomatic and asymptomatic carotid stenosis’, Scientific Reports, 10(1). Available at: https://doi.org/10.1038/s41598-020-78941-8.

Sieweke, J.-T. et al. (2020) ‘MiR−21 and nt-probnp correlate with echocardiographic parameters of atrial dysfunction and predict atrial fibrillation’, Journal of Clinical Medicine, 9(4). Available at: https://doi.org/10.3390/jcm9041118.

Grosse, G.M. et al. (2020) ‘Identification of a rare SEPT9 variant in a family with autosomal dominant Charcot-Marie-Tooth disease’, BMC Medical Genetics, 21(1). Available at: https://doi.org/10.1186/s12881-020-0984-7.

Grosse, G.M. et al. (2020) ‘Arginine derivatives in cerebrovascular diseases: Mechanisms and clinical implications’, International Journal of Molecular Sciences, 21(5). Available at: https://doi.org/10.3390/ijms21051798.

van Gemmeren, T. et al. (2020) ‘Early post-stroke infections are associated with an impaired function of neutrophil granulocytes’, Journal of Clinical Medicine, 9(3). Available at: https://doi.org/10.3390/jcm9030872.

Sieweke, J.-T. et al. (2020) ‘Septal total atrial conduction time for prediction of atrial fibrillation in embolic stroke of unknown source: a pilot study’, Clinical Research in Cardiology, 109(2), pp. 205–214. Available at: https://doi.org/10.1007/s00392-019-01501-2.

Putzer, A.-S. et al. (2020) ‘ADAMTS13 activity is associated with early neurological improvement in acute ischemic stroke patients treated with intravenous thrombolysis’, Journal of Thrombosis and Thrombolysis, 49(1), pp. 67–74. Available at: https://doi.org/10.1007/s11239-019-01941-7.

Ziegler, N.L. et al. (2019) ‘Markers of endothelial pathology to support detection of atrial fibrillation in embolic stroke of undetermined source’, Scientific Reports, 9(1). Available at: https://doi.org/10.1038/s41598-019-55943-9.

Grosse, G.M. et al. (2019) ‘Plasma dimethylarginine levels and carotid intima–media thickness are related to atrial fibrillation in patients with embolic stroke’, International Journal of Molecular Sciences, 20(3). Available at: https://doi.org/10.3390/ijms20030730.

Kasner S.E. et al. (2018) ‘Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial’, The Lancet Neurology, 17(12), pp. 1053–1060. Available at: https://doi.org/10.1016/s1474-4422(18)30319-3.

Hart RG et al. (2018) ‘Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.’, The New England journal of medicine. 16.05.2018, 378(23), pp. 2191–2201. Available at: https://doi.org/10.1056/nejmoa1802686.

Schuppner, R. et al. (2018) ‘ADAMTS-13 Activity Predicts Outcome in Acute Ischaemic Stroke Patients Undergoing Endovascular Treatment’, Thrombosis and Haemostasis, 118(4), pp. 758–767. Available at: https://doi.org/10.1055/s-0038-1637732.

Grosse, G.M. et al. (2018) ‘Targeting chemokine receptor CXCR4 and translocator protein for characterization of high-risk plaque in carotid stenosis ex vivo’, Stroke, 49(8), pp. 1988–1991. Available at: https://doi.org/10.1161/STROKEAHA.118.021070.

Grosse, G.M. et al. (2016) ‘Monocyte subsets and related chemokines in carotid artery stenosis and ischemic stroke’, International Journal of Molecular Sciences, 17(4). Available at: https://doi.org/10.3390/ijms17040433.

Grosse, G.M. et al. (2014) ‘Re. “identification of patients with a histologically unstable carotid plaque using ultrasonic plaque image analysis”’, European Journal of Vascular and Endovascular Surgery, 48(6), pp. 714–715. Available at: https://doi.org/10.1016/j.ejvs.2014.09.013.

Grosse, G.M. et al. (2014) ‘The temporal dynamics of plasma fractalkine levels in ischemic stroke: Association with clinical severity and outcome’, Journal of Neuroinflammation, 11. Available at: https://doi.org/10.1186/1742-2094-11-74.